Supplementary material BMJ Open

Supplement 1A. Antineoplastic samples of the intervention group

Generic Name ATC Classfication Manufactures1 Indications Approved in China L01DB04 originator only acute leukemia; malignant lymphoma; ovarian ; small cell lung cancer; malignant L01XX03 chemotherapy generic only lymphoma; endometrial ; acute lymphoblastic leukemia, ALL; acute myeloid originator and leukemia, AML; acute monocytic leukemia, AMOL; L01XX02 chemotherapy generic chronic myeloid leukemia, CML; Hodgkin's lymphoma; non-Hodgkin's lymphoma; melanoma; Cutaneous Carcinoma; head and neck cancer; lung cancer; originator and L01DC01 chemotherapy esophageal cancer; malignant lymphoma; cervical generic carcinoma; neuroglioma; thyroid carcinoma; chronic myeloid leukemia; Essential Thrombocythemia, L01AB01 chemotherapy originator only polycythemia vera and other chronic myeloproliferative disorders, CMPDs originator and ovarian cancer; small cell lung cancer; head and neck L01XA02 chemotherapy generic squamous cell carcinoma; gastrointestinal cancer(colon cancer, colorectal cancer, L01BC04 chemotherapy generic only gastric cancer, esophagus cancer); breast cancer; encephaloma; brain metastases; meningeal leukemia; L01AD01 chemotherapy generic only malignant lymphoma; multiple myeloma; malignant melanoma; L01AX04 chemotherapy generic only melanoma; soft tissue tumor; malignant lymphoma;

Guan X, et al. BMJ Open 2019; 9:e031658. doi: 10.1136/bmjopen-2019-031658 Supplementary material BMJ Open

, AML; acute lymphoblastic L01DB02 chemotherapy generic only leukemia, ALL; originator and L01CD02 chemotherapy breast cancer; non-small cell lung cancer; generic Breast cancer; gastric cancer; colorectal cancer; / chemotherapy generic only nasopharyngeal cancer； leukemia; malignant lymphoma; multiple myeloma; breast originator and L01DB03 chemotherapy cancer; lung cancer; soft tissue tumor; gastric cancer; liver generic cancer; colorectal cancer; ovarian cancer; small cell lung cancer; malignant lymphoma; leukemia; neuroblastoma; rhabdomyosarcom; gastric cancer; L01CB01 chemotherapy generic only esophageal carcinoma; malignant germ cell tumor; ovarian cancer; originator and L01BB05 chemotherapy chronic lymphocytic leukemia; generic Gastrointestinal Cancer; chorionepithilioma; breast cancer; L01BC02 chemotherapy generic only Ovarian Carcinoma; lung cancer; cervical carcinoma; bladder cancer; skin cancer; originator and non-small cell lung cancer; pancreatic cancer; breast L01BC05 chemotherapy generic cancer; primary liver cancer; gastric cancer; bladder cancer; rectal originator and hydroxycamptothecin / chemotherapy cancer; head and neck epithelial cancer; leukemia and other generic malignant tumors breast cancer; small cell lung cancer; chronic myeloid lobaplatin / chemotherapy originator only leukemia

Guan X, et al. BMJ Open 2019; 9:e031658. doi: 10.1136/bmjopen-2019-031658 Supplementary material BMJ Open

Solid tumors such as head and neck cancer, small cell lung / chemotherapy generic only cancer, non-small cell lung cancer and esophageal cancer originator and brian tumor; gastrointestinal cancer; lung cancer; malignant L01AD06 chemotherapy generic lymphoma; chronic leukemia; originator and L01XA03 chemotherapy colorectal carcinoma; hepatocellular carcinoma, HCC; generic brain tumor; malignant lymphoma; gastric cancer; colon L01AD03 chemotherapy generic only cancer; melanoma; L01BC03 chemotherapy generic only Gastrointestinal Cancer; breast cancer; tegafur, gimeracil and gastrointestinal cancer( gastric cancer; intestinal cancer; L01BC53 chemotherapy generic only oteracil porassium pancreatic cancer); breast cancer; liver cancer; originator and L01AX03 chemotherapy glioblastoma multiforme, GBM; anaplastic astrocytoma; generic originator and malignant lymphoma; central nervous system-tumors; L01CB02 chemotherapy generic bladder cancer; originator and L01XX17 chemotherapy small cell lung cancer; ovarian cancer; generic non-small cell lung cancer; small cell lung cancer; L01CA03 chemotherapy generic only malignant lymphoma; breast cancer; esophageal carcinoma; malignant melanoma; originator and L01CA04 chemotherapy non-small cell lung cancer; breast cancer; generic 1 Manufactures of specific medications during our study period.

Guan X, et al. BMJ Open 2019; 9:e031658. doi: 10.1136/bmjopen-2019-031658 Supplementary material BMJ Open

Supplement 1B. Antineoplastic medications samples of the control group Generic Name ATC Classfication Manufactures1 Indications Approved in China Hodgkin's disease; neuroblastoma; choriocarcinoma; originator and actinomycin D L01DA01 chemotherapy testicular cancer; Wilms'tumor; Ewing's sarcoma; generic rhabdomyosarcoma L01XX01 chemotherapy generic only acute leukemia; malignant lymphoma; arsenite L01XX27 chemotherapy generic only acute promyelocytic leukemia, APL; liver cancer; originator and L01XX32 targeted therapy multiple myeloma; mantle cell lymphoma; generic cetuximab L01XC06 targeted therapy originator only colorectal cancer; originator and L01BC08 chemotherapy myelodysplastic syndrome(MDS); generic acute myeloid leukemia; lymphoma; soft tissue tumor and originator and L01DB01 chemotherapy osteosarcoma; chlidren malignant tumour; solid tumor in generic adults; particularly breast cancer and lung cancer; erlotinib L01XE03 targeted therapy originator only non-small cell lung cancer; liver cancer; rectum cancer; esophageal cancer; gastric L01BC09 chemotherapy generic only cancer; breast cancer;lung cancer; fluorouracil L01BC52 chemotherapy generic only gastrointestinal cancer; breast cancer; liver cancer; combinations gefitinib L01XE02 targeted therapy originator only non-small cell lung cancer; acute myeloid leukemia, AML; acute lymphoblastic L01DB06 chemotherapy originator only leukemia, ALL;

Guan X, et al. BMJ Open 2019; 9:e031658. doi: 10.1136/bmjopen-2019-031658 Supplementary material BMJ Open

originator and chronic myeloid leukemia, CML; gastrointestinal stromal imatinib L01XE01 targeted therapy generic tumors, GIST; acute lymphoblastic leukemia, ALL; L01BA03 chemotherapy originator only colorectal cancer; follicle Center Lymphomas; follicular non-Hodgkin's rituximab L01XC02 targeted therapy originator only lymphom; diffuse large B-cell lymphoma; renal cell cancer, RCC; gastrointestinal stromal tumors, sunitinib L01XE04 targeted therapy originator only GIST; pancreatic neuroendocrine tumors, pNET; renal cell cancer; hepatocellular carcinoma; thyroid sorafenib L01XE05 targeted therapy originator only cancer; acute lymphocytic leukemia; acute non-lymphocytic L01BB03 chemotherapy generic only leukemia; chronic myeloid leukemia; nilotinib L01XE08 targeted therapy originator only chronic myeloid leukemia; trastuzumab L01XC03 targeted therapy originator only breast cancer; gastric cancer; breast cancer; ovarian cancer; bladder cancer; L01AC01 chemotherapy generic only gastrointestinal cancer; acute leukemia; Hodgkin's lymphoma; malignant L01CA01 chemotherapy generic only melanoma; breast cancer; bronchogenic carcinoma; soft tissue sarcoma; neuroblastoma; 1 Manufactures of specific medications during our study period.

Guan X, et al. BMJ Open 2019; 9:e031658. doi: 10.1136/bmjopen-2019-031658